
Implantica
33,5
SEK
+0,6 %
Mindre end 1K følgere
IMP A SDB
First North Stockholm
Medical Equipment & Services
Health Care
Overview
Finansielt overblik og estimater
Ownership
+0,6%
-22,09%
-2,62%
-3,32%
-23,34%
+13,95%
-28,87%
-
-65,31%
Implantica is active in medical technology. The company specializes in the development of medical devices. The product portfolio is broad and includes implantable medical instruments, which are further used for the treatment of diseases that affect the esophagus. In addition to the main business, service and related ancillary services are also offered, especially focused on eHealth. Implantica operates worldwide, with the largest presence in North America and Europe.
Læs mereMarkedsværdi
39,63 mia. SEK
Aktieomsætning
67,04 t SEK
Omsætning
22,25 mio.
EBIT %
-1.312,89 %
P/E
-
Udbytteafkast, %
-
Finanskalender
9.5
2025
Delårsrapport Q1'25
15.5
2025
Generalforsamling '25
14.8
2025
Delårsrapport Q2'25
ViserAlle indholdstyper

Implantica publishes Year-end Report, January - December 2024 (Q4)
Implantica announces positive feedback received from U.S. FDA of the RefluxStop™ PMA Module 2 submission
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Implantica announces Module 1 is accepted and closed by FDA in the PMA application for RefluxStop™
Implantica presents the Year-end Report (Q4 2024) on February 14 at 15:00 CET
Implantica announces onboarding of the world-leading La Paz University Hospital, Spain
Implantica announces completion of first GI-focused RefluxStop™ educational meeting by a prestigious NHS Hospital in the UK
Implantica announces new exceptional published data from the largest real-world study from Germany
Implantica announces the payment of share rewards based on the AGM approved share-based incentive program as a directed share issue of own shares of the company without consideration
Implantica to be included in Nasdaq's First North 25 index
Implantica strengthens the strategic RefluxStop™ expansion with the addition of yet another key University Hospital in Germany with several more in the pipeline
Implantica announces two new RefluxStop™ University Hospitals in Spain, leading to 10 active centers and many more to join soon
Implantica deepens market penetration in Italy with the addition of the ninth RefluxStop™ Center of Excellence and several lined up to start near-term
